Skip to content

Raloxifene

Raloxifene (Evista) is used for postmenopausal osteoporosis and to reduce breast cancer risk in postmenopausal women. This page covers the one formulation listed in the catalogue.

Medicine containing Raloxifene

Evista

Postmenopausal Osteoporosis, Breast Cancer

60mg

Raloxifene tablets for postmenopausal osteoporosis and breast cancer. It mimics oestrogen in bone but opposes it in breast tissue.

From$0.80/ tabletView

Key points

  • Raloxifene is a selective oestrogen receptor modulator: it mimics oestrogen in bone but blocks oestrogen receptors in breast tissue.
  • The only strength in the catalogue is 60mg, and the only form is a tablet.

Evista is the brand name for raloxifene, marketed by originator Eli Lilly. Raloxifene is listed for postmenopausal osteoporosis and breast cancer, and falls under the Oncology Support category.

Further reading